Marisa Roberto | |
---|---|
Born | c. 1971 |
Nationality | Italian-American |
Citizenship | Italy and United States |
Alma mater | University of Pisa |
Known for | Effects of alcohol and neuropeptides on synaptic transmission in the central amygdala. |
Awards | Presidential Early Career Awards for Scientists and Engineers (PECASE), 2009; Knight of the “Order of Merit of the Republic of Italy”, 2011; The Jacob P. Waletzky Award from the Society for Neuroscience, 2016 |
Scientific career | |
Fields | Neuropharmacology, Neuroscience and Addiction |
Institutions | The Scripps Research Institute |
Academic advisors | Marcello Brunelli, Donna Gruol, and George R. Siggins |
Website | www |
Marisa Roberto is an Italian-American neuroscientist and professor in the Department of Molecular Medicine and Neuroscience at The Scripps Research Institute in La Jolla, California. Roberto is recognized for her contributions to the understanding of alcohol addiction, specifically for her research on the effects of alcohol and neuromodulators (e.g., neuropeptides and neuroimmune mediators) on synaptic transmission in the central amygdala, a critical addiction-related brain region.
Marisa Roberto was born in Volterra, Italy in 1971. Her parents Maria Gemma and Immacolato Roberto own agricultural land for farming. She is one of four siblings and is the middle child of her two living brothers. She was the only one to pursue higher education and is a first generation high school, college, and doctoral graduate.
Roberto pursued a B.A. in biology from the University of Pisa. She completed her experimental thesis titled "Mechanisms of modulation of the Na+/K+-ATPasic pump in the T neurons of the leech Hirudo medicinalis by a sea-weed biotoxin," and graduated with distinction in 1996. She went on to complete her Ph.D. in Basic Neuroscience under the mentorship of Dr. Marcello Brunelli from the University of Pisa in 2001. Her graduate worked focused on the effects of the neuropeptide, PACAP-38, on synaptic transmission and long-term potentiation, a neural correlate of learning and memory, in the rodent hippocampus. [1] [2] In 1999 during her graduate studies, Roberto joined the Department of Neuropharmacology at The Scripps Research Institute as a visiting student to study the effects of alcohol on synaptic transmission in the amygdala [3] and long-term potentiation in the hippocampus under the mentorship of Drs. George Siggins and Donna Gruol, respectively. [4] [5] After completing her Ph.D. in 2001, Roberto returned to Scripps as a postdoctoral fellow in the laboratory of Dr. George Siggins to study the neuroadaptations in synaptic transmission induced by acute and chronic alcohol in the central amygdala, [6] [7] [8] a brain region critical in mediating the behavioral effects of alcohol consumption.
In 2005, Roberto became an assistant professor in the Molecular and Integrative Neuroscience Department at the Scripps Research Institute and then the Committee on Neurobiology of Addictive Disorders in 2006. Roberto's research demonstrated the role of pro- and anti-stress neuropeptidergic (e.g. corticotropin-releasing factor, nociceptin, and neuropeptide Y) signaling on GABAergic transmission in the central amygdala following excessive drinking and alcohol dependence.
In 2015, Roberto was promoted to a tenured professor position and became an adjunct professor in the Department of Psychiatry at the University of California San Diego. In 2016, Roberto received a merit award from the National Institute for Alcohol Abuse and Alcoholism to study the effects of the brain stress peptide, corticotropin-releasing factor and endocannabinoids, on stress-induced alcohol seeking and anxiety-like behaviors in Alcohol Preferring msP rats - to assess gene-environment interactions. [9]
Roberto is the scientific director of the Integrative Neuroscience Initiative on Alcoholism (INIA) Neuroimmune consortium, [10] the scientific director of The Scripps Research Institute's Alcohol Research Institute, [11] and a researcher in The Pearson Center for Alcoholism and Addiction Research. [12] She serves as a senior editor on the editorial board for Neuropharmaology since 2016 and organizes the triennial international meeting on 'Alcoholism and Stress: A Framework for Future Treatment Strategies' in her hometown Volterra, Italy (2008, 2011, 2014, 2017, and 2020). [13] [14] [15]
Roberto won the Young Investigator Award from the Research on Alcoholism in 2005 and from the European Society for Biomedical Research on Alcoholism in 2007. She was a recipient of the Presidential Early Career Awards for Scientists and Engineers from President Barack Obama in the United States in 2009. [16] Roberto was awarded the Cavaliere (knight) degree of the Order of Merit of the Republic of Italy, the nation's highest honor, for her research contributions to the neurobiology of addictive behavior in 2011. [17] Roberto also received the Jacob P. Waletzky Award, recognizing innovative research in drug addiction and alcoholism, from the Society of Neuroscience in 2016. [4]
Neuropeptide Y (NPY) is a 36 amino-acid neuropeptide that is involved in various physiological and homeostatic processes in both the central and peripheral nervous systems. It is secreted alongside other neurotransmitters such as GABA and glutamate.
Neuropharmacology is the study of how drugs affect function in the nervous system, and the neural mechanisms through which they influence behavior. There are two main branches of neuropharmacology: behavioral and molecular. Behavioral neuropharmacology focuses on the study of how drugs affect human behavior (neuropsychopharmacology), including the study of how drug dependence and addiction affect the human brain. Molecular neuropharmacology involves the study of neurons and their neurochemical interactions, with the overall goal of developing drugs that have beneficial effects on neurological function. Both of these fields are closely connected, since both are concerned with the interactions of neurotransmitters, neuropeptides, neurohormones, neuromodulators, enzymes, second messengers, co-transporters, ion channels, and receptor proteins in the central and peripheral nervous systems. Studying these interactions, researchers are developing drugs to treat many different neurological disorders, including pain, neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, psychological disorders, addiction, and many others.
Sensitization is a non-associative learning process in which repeated administration of a stimulus results in the progressive amplification of a response. Sensitization often is characterized by an enhancement of response to a whole class of stimuli in addition to the one that is repeated. For example, repetition of a painful stimulus may make one more responsive to a loud noise.
George F. Koob is a Professor and former Chair of the Committee on the Neurobiology of Addictive Disorders at the Scripps Research Institute and Adjunct Professor of Psychology, Psychiatry, and Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego. In 2014 he became the director of the National Institute on Alcohol Abuse and Alcoholism.
Corticotropin-releasing hormone receptor 1 (CRHR1) is a protein, also known as CRF1, with the latter (CRF1) now being the IUPHAR-recommended name. In humans, CRF1 is encoded by the CRHR1 gene at region 17q21.31, beside micrototubule-associated protein tau MAPT.
Psychological dependence is a cognitive disorder that involves emotional–motivational withdrawal symptoms – such as anxiety or anhedonia – upon cessation of prolonged drug abuse or certain repetitive behaviors. It develops through frequent exposure to certain psychoactive substances or behaviors, which leads to an individual requiring further exposure to avoid withdrawal symptoms, as a result of negative reinforcement. Neuronal counter-adaptation is believed to play a role in generating withdrawal symptoms, which could be mediated through changes in neurotransmitter activity or altered receptor expression. Environmental enrichment and physical activity can attenuate withdrawal symptoms.
Protein fosB, also known as FosB and G0/G1 switch regulatory protein 3 (G0S3), is a protein that in humans is encoded by the FBJ murine osteosarcoma viral oncogene homolog B (FOSB) gene.
Alcohol withdrawal syndrome (AWS) is a set of symptoms that can occur following a reduction in alcohol use after a period of excessive use. Symptoms typically include anxiety, shakiness, sweating, vomiting, fast heart rate, and a mild fever. More severe symptoms may include seizures, and delirium tremens (DTs); which can be fatal in untreated patients. Symptoms start at around 6 hours after last drink. Peak incidence of seizures occurs at 24-36 hours and peak incidence of delirium tremens is at 48-72 hours.
The short-term effects of alcohol consumption range from a decrease in anxiety and motor skills and euphoria at lower doses to intoxication (drunkenness), to stupor, unconsciousness, anterograde amnesia, and central nervous system depression at higher doses. Cell membranes are highly permeable to alcohol, so once it is in the bloodstream, it can diffuse into nearly every cell in the body.
Ethanol is the type of alcohol found in alcoholic beverages. It is a volatile, flammable, colorless liquid that acts as a central nervous system depressant. Ethanol can impair different types of memory.
Addiction is a neuropsychological disorder characterized by a persistent and intense urge to use a drug or engage in a behaviour that produces natural reward, despite substantial harm and other negative consequences. Repetitive drug use often alters brain function in ways that perpetuate craving, and weakens self-control. This phenomenon – drugs reshaping brain function – has led to an understanding of addiction as a brain disorder with a complex variety of psychosocial as well as neurobiological factors that are implicated in addiction's development. Classic signs of addiction include compulsive engagement in rewarding stimuli, preoccupation with substances or behavior, and continued use despite negative consequences. Habits and patterns associated with addiction are typically characterized by immediate gratification, coupled with delayed deleterious effects.
ORG-25935, also known as SCH-900435 is a synthetic drug developed by Organon International, which acts as a selective inhibitor of the glycine transporter GlyT-1. In animal tests it reduces alcohol consumption and has analgesic and anticonvulsant effects, but it has mainly been studied for its antipsychotic properties, and in human trials it was shown to effectively counteract the effects of the dissociative drug ketamine.
Addiction is a state characterized by compulsive engagement in rewarding stimuli, despite adverse consequences. The process of developing an addiction occurs through instrumental learning, which is otherwise known as operant conditioning.
The central nucleus of the amygdala is a nucleus within the amygdala. It "serves as the major output nucleus of the amygdala and participates in receiving and processing pain information."
While researchers have found that moderate alcohol consumption in older adults is associated with better cognition and well-being than abstinence, excessive alcohol consumption is associated with widespread and significant brain lesions. Other data – including investigated brain-scans of 36,678 UK Biobank participants – suggest that even "light" or "moderate" consumption of alcohol by itself harms the brain, such as by reducing brain grey matter volume. This may imply that alternatives and generally aiming for lowest possible consumption could usually be the advisable approach.
Addiction vulnerability is an individual's risk of developing an addiction during their lifetime. There are a range of genetic and environmental risk factors for developing an addiction that vary across the population. Genetic and environmental risk factors each account for roughly half of an individual's risk for developing an addiction; the contribution from epigenetic risk factors to the total risk is unknown. Even in individuals with a relatively low genetic risk, exposure to sufficiently high doses of an addictive drug for a long period of time can result in an addiction. In other words, anyone can become an individual with a substance use disorder under particular circumstances. Research is working toward establishing a comprehensive picture of the neurobiology of addiction vulnerability, including all factors at work in propensity for addiction.
Alcoholism is a chronic disease characterized by trouble controlling the consumption of alcohol, dependence, and withdrawal upon rapid cessation of drinking. According to ARDI reports approximately 88,000 people had alcohol-related deaths in the United States between the years of 2006 and 2010. Furthermore, chronic alcohol use is consistently the third leading cause of death in the United States. In consequence, research has sought to determine the factors responsible for the development and persistence of alcoholism. From this research, several molecular and epigenetic mechanisms have been discovered.
Epigenetics of anxiety and stress–related disorders is the field studying the relationship between epigenetic modifications of genes and anxiety and stress-related disorders, including mental health disorders such as generalized anxiety disorder (GAD), post-traumatic stress disorder, obsessive-compulsive disorder (OCD), and more. These changes can lead to transgenerational stress inheritance.
Courtney A. Miller is an American neuroscientist and Professor of the Department of Molecular Medicine at the Scripps Research Institute in Jupiter, Florida. Miller investigates the biological basis of neurological and neuropsychiatric diseases and develops novel therapeutics based on her mechanistic discoveries.
Jessica Barson is an American neuroscientist and associate professor at Drexel University College of Medicine. Barson investigates neuropeptide signalling in the paraventricular nucleus of the thalamus as well as the nucleus accumbens to understand the neurobiological basis of addiction and elucidate targets for therapy.